Regardless, the company is still making money, and the sales upside has strengthened Abiomed's balance sheet. The company remains debt free, with roughly $71 million in cash, cash equivalents, and short-term investments on its books. Pumping up sales. Abiomed has been around since 1981, but share prices really took off in 2013 thanks to rising demand for the company's Impella product line, which includes catheters, sensors, and pumps used to boost circulation before, during, and after heart surgery.